X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA JUBILANT LIFE SCIENCES GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 19.0 13.5 140.8% View Chart
P/BV x 3.4 2.7 122.8% View Chart
Dividend Yield % 0.3 0.4 73.1%  

Financials

 GLENMARK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-18
GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs9301,039 89.5%   
Low Rs517600 86.2%   
Sales per share (Unadj.) Rs322.6482.6 66.9%  
Earnings per share (Unadj.) Rs28.540.7 70.0%  
Cash flow per share (Unadj.) Rs39.267.4 58.2%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.4 75.5%  
Book value per share (Unadj.) Rs183.0262.3 69.8%  
Shares outstanding (eoy) m282.17155.79 181.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.21.7 132.1%   
Avg P/E ratio x25.420.1 126.2%  
P/CF ratio (eoy) x18.512.2 151.8%  
Price / Book Value ratio x4.03.1 126.6%  
Dividend payout %7.07.4 95.3%   
Avg Mkt Cap Rs m204,206127,670 159.9%   
No. of employees `00013.72.4 563.1%   
Total wages/salary Rs m18,71815,559 120.3%   
Avg. sales/employee Rs Th6,636.830,861.4 21.5%   
Avg. wages/employee Rs Th1,364.76,387.0 21.4%   
Avg. net profit/employee Rs Th586.12,604.4 22.5%   
INCOME DATA
Net Sales Rs m91,03175,178 121.1%  
Other income Rs m914400 228.3%   
Total revenues Rs m91,94575,579 121.7%   
Gross profit Rs m16,15415,184 106.4%  
Depreciation Rs m3,0194,151 72.7%   
Interest Rs m2,8562,843 100.5%   
Profit before tax Rs m11,1938,591 130.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1552,247 140.4%   
Profit after tax Rs m8,0396,344 126.7%  
Gross profit margin %17.720.2 87.9%  
Effective tax rate %28.226.2 107.8%   
Net profit margin %8.88.4 104.6%  
BALANCE SHEET DATA
Current assets Rs m69,88731,898 219.1%   
Current liabilities Rs m32,87920,047 164.0%   
Net working cap to sales %40.715.8 257.9%  
Current ratio x2.11.6 133.6%  
Inventory Days Days8168 120.5%  
Debtors Days Days9355 170.3%  
Net fixed assets Rs m28,89260,715 47.6%   
Share capital Rs m282156 181.1%   
"Free" reserves Rs m51,35340,710 126.1%   
Net worth Rs m51,63540,865 126.4%   
Long term debt Rs m41,41830,478 135.9%   
Total assets Rs m125,95496,176 131.0%  
Interest coverage x4.94.0 122.3%   
Debt to equity ratio x0.80.7 107.6%  
Sales to assets ratio x0.70.8 92.5%   
Return on assets %8.69.6 90.5%  
Return on equity %15.615.5 100.3%  
Return on capital %15.116.0 94.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31714,402 252.2%   
Fx outflow Rs m9,72012,044 80.7%   
Net fx Rs m26,5982,358 1,128.0%   
CASH FLOW
From Operations Rs m16,48113,032 126.5%  
From Investments Rs m-10,133-6,177 164.1%  
From Financial Activity Rs m-4,685-9,011 52.0%  
Net Cashflow Rs m1,770-2,123 -83.4%  

Share Holding

Indian Promoters % 48.3 45.6 105.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 6.9 8.7 79.3%  
FIIs % 34.4 21.2 162.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.1 49.8%  
Shareholders   56,727 23,815 238.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  SANOFI INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

A 90% Chance of Auto Stocks Moving Up This April(Profit Hunter)

Apr 5, 2019

The Auto index ended on a positive note in the month of April in 9 out of last 10 years. This Auto stock is best placed to benefit from the upswing in this sector.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS